BMS’ Opdivo Continues to Impress at ESMO
Monday, October 10, 2016
Bristol Myers Squibb's immunotherapy Opdivo not only extends survival in patients with a certain type of head and neck cancer but data, presented at the European Society of Medical Oncology congress, also show improvements on quality of life measures.
Patient-reported quality-of-life data from the pivotal Phase III CheckMate -141 trial show that, compared to treatment with investigator's choice of methotrexate, docetaxel or cetuximab, Opdivo stabilised symptoms and functioning - including physical, role and social functioning across three separate instruments - in patients with squamous cell carcinoma of the head and neck.
Both patients expressing PD-L1 and those who didn't given the investigator's choice of therapy experienced statistically significant worsening of patient-reported outcomes from baseline to week 15 versus Opdivo, the firm said.